Skip to main content
Diagnostic Medical Systems logo

Diagnostic Medical Systems — Investor Relations & Filings

Ticker · ALDMS ISIN · FR0012202497 LEI · 969500RKTIGCNNIKIN19 PA Manufacturing
Open in API
Filings indexed 232 across all filing types
Latest filing 2019-06-12 Investor Presentation
Country FR France
Listing PA ALDMS

About Diagnostic Medical Systems

https://www.dms.com/en/home/

Diagnostic Medical Systems (DMS) specializes in the development, design, and manufacturing of medical imaging systems. The company's core focus is on digital radiology and bone densitometry. Its product portfolio includes radiography and fluoroscopy systems, mobile x-ray units, surgical C-arms, and bone densitometers. DMS is engaged in developing next-generation imaging solutions aimed at improving patient care and personalized medicine. Key development projects include new mobile and surgical imaging equipment and an advanced range of bone densitometers for diagnosing and monitoring pathologies affecting bone mineral density.

Recent filings

Filing Released Lang Actions
Le projet arthrose de DMS Biotech : une réponse simple, peu coûteuse et efficace à un besoin médical non satisfait
Investor Presentation Classification · 99% confidence The document is a detailed press release from DMS Biotech (a division of DMS Group) dated June 12, 2019. It discusses the positive results of a clinical trial for their arthrosis treatment using adipose-derived stem cells. The text focuses on explaining the medical problem (arthrosis), reviewing current inadequate treatments, detailing their innovative, simple, and cost-effective therapeutic protocol, and concluding with company background information. This format—a detailed update on a specific business/product development, often following a clinical milestone or trial result announcement—is characteristic of an Investor Presentation (IP) or a detailed press release that functions as one. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a simple earnings release (ER), and it provides strategic and technical depth aimed at investors, 'Investor Presentation' (IP) is the most fitting category, even if presented as a news release. It is too detailed to be a simple Report Publication Announcement (RPA).
2019-06-12 French
Extension des accords commerciaux et industriels avec Fujifilm Europe au Moyen-Orient, en Afrique et en Asie
Regulatory Filings Classification · 100% confidence The document announces an extension of commercial and industrial agreements between DMS Diagnostic Medical Systems Group and Fujifilm Europe regarding medical imaging technology (BiomodTM integration and marketing of densitometry solutions). The text is dated (03/06/2019) and reads like a formal press release detailing a business development, partnership extension, and product updates (Visionary 3D GL, Stratos/Stratos dR). It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific business announcement detailing strategic developments and partnerships, it most closely aligns with a general regulatory announcement or press release that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP). Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-periodic corporate news releases that are not explicitly covered elsewhere, although 'LTR' (Legal Proceedings Report) or 'MDA' (Management Reports) are less fitting. Since it is a formal announcement of a business event, RNS is the most appropriate fallback for a non-standard filing type.
2019-06-03 French
Résultats positifs de l'essai clinique sur l'arthrose
Earnings Release Classification · 99% confidence The document announces positive results from a clinical trial concerning the use of adipose-derived cells for treating knee osteoarthritis. It details the study design (pilot, multicenter, randomized, controlled), patient follow-up, efficacy results (pain reduction, improved function, sustained effect compared to hyaluronic acid), and next steps (scientific publication, discussions with authorities). This content is characteristic of a press release detailing significant operational or scientific progress, often released before a formal regulatory filing or comprehensive report. Since it is an initial announcement of results and not a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is 'Earnings Release' (ER) as it serves as the primary communication of period-specific performance/results, or potentially 'Regulatory Filings' (RNS) if it's a general market announcement. Given the focus on clinical trial results, which are key performance indicators for a biotech/medical device company, ER is a strong fit, although it's not strictly 'financial' earnings. However, looking at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. Since this is a scientific/operational highlight, and there is no specific category for clinical trial results announcements, we must choose the best fit. It is not a management discussion (MDA), nor a general regulatory filing (RNS) if a better fit exists. Since it is an announcement of a major development/result, and it is not a formal report, 'ER' (Earnings Release, interpreted broadly as 'Key Results Announcement') or 'RNS' (Regulatory Filings/General Announcement) are candidates. Given the context of financial reporting databases, major operational milestones like this are often grouped with ERs or treated as RNS. Since it is a detailed announcement of results, and not just a short notice of publication, I will lean towards ER as the primary communication of a key outcome, or RNS as the fallback. Given the detailed nature, it is more than a simple RNS. Let's re-evaluate: It is a press release announcing scientific results. This often falls under RNS if no other category fits. Since it is not a financial earnings report, ER is weak. It is not a management report (MDA) which usually accompanies financial results. It is a specific announcement. I will classify it as RNS (Regulatory Filings/General Announcement) as the most appropriate general category for non-standard, yet important, corporate announcements that aren't explicitly defined elsewhere, although it shares characteristics with an ER in terms of being a 'results' announcement. However, if we interpret 'ER' as 'Key Performance Indicator Announcement', it fits well. Let's check the length: 7415 chars, which is substantial, suggesting it is the full announcement, not just a notice (ruling out RPA). Given the context of a company reporting on its progress, ER is often used for significant operational updates when quarterly financials aren't the focus. I will select ER based on it being a primary announcement of performance outcomes. If this were a formal filing, it would be different, but as a press release, ER is often the closest fit for major results announcements. FY 2018
2019-05-22 French
Résultats annuels 2018 - Chiffre d'affaires du 1er trimestre 2019 : +33% de croissance
Earnings Release Classification · 95% confidence The document is an earnings release (communiqué de presse) from Diagnostic Medical Systems Group. It provides a summary of the 2018 annual results and the 2019 first-quarter revenue. While it contains financial tables, it is clearly structured as a press release (highlighting key figures, management commentary, and future outlook) rather than a full statutory annual report or interim financial report. It explicitly mentions that the full financial report (including audit reports) will be made available later, confirming this document is the initial earnings announcement. Q1 2019
2019-04-29 French
24,3 M EUR de chiffre d'affaires en 2018
Earnings Release Classification · 98% confidence The document is dated February 28, 2019, and explicitly states it publishes the consolidated revenue ('chiffre d'affaires consolidé') for the fiscal year 2018, which ended December 31, 2018. It provides detailed, non-audited financial figures for the full year and the fourth quarter, along with commentary on business segments. This structure—a release of periodic financial results (annual in this case) focusing on key figures before the full audited report—is characteristic of an Earnings Release (ER). Although it covers the full year, it is presented as a preliminary announcement of the revenue figures, distinct from the comprehensive 10-K filing. The document also includes an agenda for future report publications, confirming its role as a preliminary results announcement. FY 2018
2019-02-28 French
Lettre aux actionnaires de DMS Group - Février 2019
Legal Proceedings Report Classification · 95% confidence The document is titled "Lettre aux actionnaires de DMS Group" (Letter to Shareholders of DMS Group) and is signed by the Chairman and CEO. It discusses the company's strategy, technological developments (Biomod 3S), partnerships, industrial expansion, diversification into new sectors (DMS Wellness, DMS Biotech), and potential corporate actions (spin-off of DMS Biotech via an asset contribution to Hybrigenics). This format—a direct address from top management outlining strategy, performance context, and future plans to shareholders—is characteristic of an Annual Report or a letter included within one. However, since it is presented as a standalone letter focusing heavily on strategic narrative rather than comprehensive financial statements (which would suggest a 10-K or IR), and given the context of shareholder communication, it most closely aligns with the narrative component often found in an Annual Report (10-K) or a dedicated shareholder communication. Since it is a comprehensive strategic overview rather than just a brief announcement (like RPA or ER), and it is not explicitly a formal regulatory filing like a 10-K, the best fit among the provided options that captures this high-level strategic communication to owners is often associated with the Annual Report context, or sometimes an Investor Presentation (IP) if it were slide-based. Given the narrative length and depth, it functions as a key component of the annual review. If this were a standalone document outside of the 10-K filing, it often serves as the primary shareholder communication. Given the options, and the lack of explicit financial tables suggesting a full IR, it is most likely the Chairman's letter component of an Annual Report (10-K) or a very detailed Investor Presentation (IP). Since it is a letter and not a presentation deck, and it covers the full scope of the year's strategic direction, I will classify it as highly related to the Annual Report context, but since it is a letter, it could also be an Investor Presentation (IP) if it's meant to be presented. Given the depth and the reference to future plans and past performance context, it strongly resembles the narrative section of an Annual Report (10-K). However, if we strictly adhere to the definitions, it is a strategic letter. If it were a formal regulatory filing, it would be part of the 10-K. As a standalone document, it functions as a detailed strategic update, making 'Investor Presentation' (IP) a strong candidate if it's meant for investor meetings, or 'Annual Report' (10-K) if it's the core narrative. Given the lack of explicit financial tables and the focus on strategy and future outlook, 'Investor Presentation' (IP) is a reasonable classification for a detailed strategic letter intended for investors, although '10-K' covers the annual review scope. I will lean towards 'IP' as it is a direct communication piece detailing strategy, which is the core of an investor presentation, rather than the formal regulatory filing itself.
2019-02-14 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.